
BATM Advanced Communications Ltd., together with its various group companies, delivers cutting-edge real-time technologies for both sophisticated networking solutions and advanced biomedical systems. The company operates across Israel, the United States, and Europe. It is structured into two primary business units: Networking and Cyber, and Bio-Medical. The Networking and Cyber division oversees the research, development, manufacturing, and marketing of data communication products. Its key offerings include network function virtualization, carrier Ethernet and MPLS access technologies, and systems for cyber network monitoring. This segment also provides a range of software services, such as training, technical assistance, and laboratory maintenance, in addition to undertaking construction contracts. Conversely, the Bio-Medical division concentrates on the innovation, production, commercialization, and distribution of medical products, with a particular emphasis on laboratory diagnostics and sterilization equipment. Its portfolio features molecular biology diagnostic tools and specialized systems for managing pathogenic and medical waste in critical environments like laboratories, hospitals, pharmaceutical manufacturing plants, and agricultural settings. This division also acts as a distributor for a broad array of diagnostic apparatus and medical consumables from various manufacturers. Notably, BATM has entered into a significant partnership with Novamed Ltd to collaboratively develop and market a home-use testing kit for COVID-19. Established in 1992, the company's corporate headquarters are situated in Hod Hasharon, Israel.
BATM Advanced Communications Ltd. trades as BVC.L on LSE. The company is classified in Healthcare / Medical - Instruments & Supplies and reports in GBP.
The current profile places the business in Medical - Instruments & Supplies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.
Latest available fiscal data shows £125.78M of revenue and -£15.52M of net income.
Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.
The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.
BATM Advanced Communications Ltd. can be compared against peers such as Creo Medical Limited, ECO Animal Health Group plc, ImmuPharma plc, Kooth plc, Ondine Biomedical Inc., SkinBioTherapeutics Plc.
A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.
Current signals to investigate include market capitalization of £55.05M, beta of 0.75, and return on equity of -23.7%.
This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.
Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.
BVC.L currently shows total debt of £10.36M and beta of 0.75. Missing data should be treated as a research gap, not as low risk.
Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.
No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.
Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.
No recent SEC-style filings are available for this symbol yet.
Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.
Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.
Company website: https://www.batm.com
For Israeli stocks, verify official filings and local reports before publishing the thesis.